By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Acucela Inc. 

1301 Second Avenue
Suite 1900, 19th Floor
Seattle  Washington  98101-3805  U.S.A.
Phone: 206-805-8300 Fax: 206-805-8301


SEARCH JOBS
Acucela Inc. is a clinical-stage biotechnology company focused on leveraging promising science in visual cycle modulation (VCM) to develop new methods for treating blinding eye diseases that affect tens of millions of people worldwide. The company’s orally-delivered VCM therapies, which selectively target cells within the retina to protect visual acuity, have the potential to be used to treat several devastating eye diseases, including dry age-related macular degeneration (AMD), retinopathy of prematurity, Stargardt disease and diabetic retinopathy. Acucela is also developing, with Otsuka Pharmaceutical, Rebamipide ophthalmic suspension, a Phase 3 product candidate for dry eye.

For more information, please visit www.Acucela.com.


Key Statistics


Email: investor@acucela.com
Ownership: Private

Web Site: Acucela Inc.
Employees:
Symbol: 
 



Industry
Biotechnology






Company News
Acucela Inc. Completes Enrollment In The Emixustat Hydrochloride Phase 2b/3 Clinical Trial 3/4/2014 8:54:05 AM
Seattle Biotech Acucela Inc. Sets Terms Of $162 Million Japanese IPO 2/4/2014 7:27:10 AM
Seattle Biotech Acucela Inc. Seeks $125 Million IPO in Japan to Develop Eye Drugs 12/18/2013 6:26:15 AM
Acucela Inc. Appoints Brian O’Callaghan to its Board of Directors 9/19/2013 6:34:17 AM
Acucela Inc. Reaches 50% Enrollment in the Emixustat Hydrochloride Phase 2b/3 Clinical Trial 8/28/2013 10:48:52 AM
Acucela Inc. and Otsuka Pharmaceutical Co., Ltd. Announce Phase IIa Clinical Results of Emixustat Hydrochloride (ACU-4429) in Patients with Geographic Atrophy (GA) Associated with Dry Age-Related Macular Degeneration (AMD) at Association for Research in Vision & Ophthalmology 2013 Annual Meeting 5/9/2013 7:34:59 AM
Acucela Inc. and Otsuka Pharmaceutical Co., Ltd. Announce the Initiation of a Phase 3 Clinical Trial to Evaluate Rebamipide Ophthalmic Suspension in Patients With Dry Eye Syndrome 7/19/2012 10:02:54 AM
Acucela Inc. Appoints Business Leader and Entrepreneur Michael Schutzler to the Company’s Board of Directors 6/19/2012 10:14:15 AM
Acucela Inc. Announces New Data from Its Phase 2a Trial of ACU-4429 in Patients With Advanced Dry AMD/Geographic Atrophy 5/8/2012 10:41:39 AM
Acucela Inc. to Present Multiple Posters at The Association for Research in Vision & Ophthalmology 2012 Annual Meeting 4/24/2012 10:34:10 AM
123456
//-->